Navigation Links
Sleeping sickness parasite shows how cells divide their insides

Researchers at Yale have brought to light a mechanism that regulates the way an internal organelle, the Golgi apparatus, duplicates as cells prepare to divide, according to a report in Science Express.

Graham Warren, professor of cell biology, and his colleagues at Yale study Trypanosoma brucei, the parasite that causes Sleeping Sickness. Like many parasites, it is exceptionally streamlined and has only one of each internal organelle, making it ideal for studying processes of more complex organisms that have many copies in each cell.

When thinking about how cells divide, doubling and separating DNA in chromosomes is often the focus. Equally important is the way a cell prepares its internal organelles for distribution. Warren studies the Golgi complex, a membrane compartment in the cytoplasm that delivers newly-made proteins to different membranes in the cell.

"Basal bodies in particular and centrosomes in general have been implicated in the biogenesis of a number of membrane-bound organelles," said Warren. "It prompted us to study further their role in Golgi duplication."

Warren's group has identified a new cellular structure, distinct from the basal body, involved in the duplication of the Golgi apparatus and defined by a highly-conserved protein, Centrin2. This structure has two lobes -- one at the old Golgi, the other where the new Golgi forms. Once a new Golgi has grown, the Centrin structure itself duplicates so that two complete structures, and associated Golgi, are ready to be allocated to daughter cells.

Significant recent advances in the molecular genetics of trypanosomes by Elisabetta Ullu and Christian Tschudi's group at Yale, allowed direct man
'"/>

Source:Yale University


Page: 1 2

Related biology news :

1. Sleeping Sickness Epidemic Spreading in Uganda
2. Sleeping beauty plays a significant role in identifying cancer genes
3. Newly discovered protein an important tool for sleeping sickness research
4. Compound might defeat African sleeping sickness, clinical trial beginning this month
5. A large step forward in the fight against African sleeping sickness
6. Resistance and genetic sensitivity to sleeping sickness
7. New study suggests promising drug combinations for sleeping sickness
8. Scientists reveal molecular secrets of the malaria parasite
9. Protein offers way to stop microscopic parasites in their tracks
10. A human parasite with a streamlined mitochondrion
11. Invasive parasite destroying fish species

Post Your Comments:
(Date:11/25/2009)...ital to your health as what you eat, found researc... Their experiments in mice revealed that the daily...verthe body,s metabolic clearinghouseis mostly con...dian clock as conventional wisdom had it. , "If...umber of genes completely independent of the circa...
(Date:11/24/2009)...es from collapsing have been true life-savers. But...ed -- once the arteries are strengthened, they bec... but to leave them in place. , Prof. Meital Zilb...dical Engineering has developed a new patent-pendi... needed, then dissolves. , "Our new composite fi...
(Date:11/24/2009)...debate. A high-profile study a few years ago sugge...on from trees and leaves, evidence for a very clos...ems. , But new research from the University of W...ae provide a much richer diet for fish and other a...week in the Proceedings of the National Academy o...
Breaking Biology News(10 mins):Feeding the clock 2Feeding the clock 3A coating for life 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 4762 1Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 4762 2Accent on Aesthetics Plastic Surgery Medical Center Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 4762 3Go to the doctor 3F Only if Im really sick 52314 1Go to the doctor 3F Only if Im really sick 52314 2Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 1Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 2Michael J Fox Foundation Awards 243 8 Million To Drive Nine Industry Partnerships For Pre Clinical Parkinsons Drug Development 52311 3
...ngs about the causes of mad cow disease show that ...also in the genes of cattle," said Juergen A. Rich...edicine and Pathobiology at Kansas State Universit...al years ago, Richt said, it was thought that the ...thy -- also called BSE or mad cow disease -- was a...
...Stevens Institute of Technology has been awarded a...e project, "MRI: Acquisition of an Inductively Cou...abrication." The Stevens team includes Yong Shi, t...gineering department; Stefan Strauf, a Professor t...e Professor in the Mechanical Engineering departme...
...t Service Southern Research Station (SRS) today an...t Disturbances: Wildfires, Storms, and Invasive Sp...ffers a synthesis of new approaches to understandi...s. , The Economics of Forest Disturbances is th...e framework for analyzing the economic effects of ...
Other Biology News:K-State professor's USDA research shows mad cow disease also caused by genetic mutation 2NSF awards two grants to Stevens for nano/micro device fabrication and nano sensor development 2Book breaks new ground in the study of economics and forest threats management 2
(Date:11/24/2009)..., , REDWOOD CITY, Calif., Nov. 24 /PRNe... GHDX ) today announced that Randy Scott, Genomic...21st Annual Piper Jaffray Health Care Conference i...:00 a.m. ET. ,, To access the live and subsequ...the Investor Relations section of Genomic Health,s...
(Date:11/24/2009)..., Program Connects Custom... Samples Collected with DNA Genotek Products , ...24, 2009 -- DNA Genotek , a leading provider of p...ation and preparation, today announced its new glo...t enhancements for DNA Genotek,s partner community...
(Date:11/24/2009)..., , SEATTLE, Nov. 24 /PRNewswire-Firs...d MTA: CTIC) management will present at the 21st A...nference will be held December 1-2, 2009, at the N...Tuesday, December 1 at 11:00 a.m. Eastern Time in ...s presentation will be available at www.cellthera...
(Date:11/23/2009)..., CHAMPAIGN, Ill. You can think of it as origami...iversity of Illinois have developed a technique fo...e silicon structures from thin films by coupling p...by capillary interactions. , The films, only a fe... is not possible with thicker pieces of the same m...
Breaking Biology Technology:Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Water droplets direct self-assembly process in thin-film materials 2
... 12 Anthera Pharmaceuticals, Inc., a,privately he...mmatory drugs,announced today that it has complete...urrent Acute coronary events with Near-term Cardio...designed to examine the impact of,varespladib (A-0...of an Acute,Coronary Syndrome (ACS) event. , "...
... Pharmasset, Inc. (Nasdaq: VRUS ) announced toda...have agreed with the FDA on the final design for a... of hepatitis C (HCV), slated to initiate in the f...at R7128 is advancing into a large phase 2b trial,...ief Medical Officer. "R7128 is the most advanced n...
...nuary 12 , - Reflects Strong International Gr...ding IP Management Specialist and Legal Support Se...llectual property,( http://www.cpaglobal.com ) (IP...outsourced legal support services, has today marke...ew brand worldwide. , Founded in 1969 as a spe...
Other Biology Technology:Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 2Anthera Completes Enrollment and Dosing of Varespladib Cardiovascular Trial 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 2Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 3Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 4Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients 5CPA Global Marks 40th Anniversary With Launch of New Brand 2CPA Global Marks 40th Anniversary With Launch of New Brand 3
GIBCO Fetal Bovine Serum Heat-Inactivated from Invitrogen
Mouse Anti-EGFr VIII Antibody, Unconjugated from Invitrogen
Custom siRNA, PAGE purified from Ambion
GIBCO Kanamycin Sulfate from Invitrogen
Biology Products: